AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 302 min read$NTRA

Sheena Jonathan sold $124K of NTRA

Sheena Jonathan sold 479 shares of Natera, Inc. (NTRA) at an average of $257.93 ($254.07–$260.49, $0.12M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jul 30, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides transparency on insider selling activity but does not include new operational or financial fundamentals for Natera.

02

Market read

For traders, the main actionable element is sentiment monitoring around insider activity; fundamental impact is likely limited absent other catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or financing news, the signal is usually weak.

Relevance 3/10Novelty 3/10Timing: after-hours filing disclosure on 2026-07-29 for sales executed 2026-07-27 to 2026-07-28

Background

The article is an SEC Form 4 insider transaction for Natera, Inc. reported by director Sheena Jonathan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about $123.5K of NTRA shares via a 10b5-1 plan on 2026-07-27 to 2026-07-28.

Expected impact

Likely minimal price impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed size is modest relative to typical large-cap trading flows.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a change in outlook.

Key entities

  • issuer
    Natera, Inc.

    Company whose director insider sale is disclosed on Form 4.

  • insider
    Sheena Jonathan

    Director who executed two open-market sales under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min
AUG 14
$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

fool.com6 min
AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min